To the full analysis
Avita Medical stock: growth
RCELAvita Medical reported $71.61M in revenue for fiscal 2025, up 11.5% on the prior year, up 38.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
27.8%
per year from 2006 to 2025, per share 14.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2019 | since 2014 | since 2006 | |
|---|---|---|---|
| Revenue | 38.1% | 53.3% | 27.8% |
| Revenue per share | 29.6% | 24.7% | 14.7% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $862.11K | −$15.07M | −$8.39M |
| 2007 | $1.25M | −$12.14M | −$3.55M |
| 2008 | $2.19M | −$5.18M | −$4.4M |
| 2009 | $2.81M | −$5.93M | −$1.78M |
| 2010 | $3.12M | −$1.95M | −$2.77M |
| 2011 | $3.43M | −$7.5M | −$4.44M |
| 2012 | $3.04M | −$8.75M | −$8.13M |
| 2013 | $2.86M | −$5.48M | −$6.83M |
| 2014 | $997.09K | −$10.34M | −$7.06M |
| 2015 | $1.34M | −$13.77M | −$7.35M |
| 2016 | $1.54M | −$15.03M | −$8.85M |
| 2017 | $1.7M | −$23.37M | −$13.32M |
| 2018 | $7.83M | −$35.9M | −$29.63M |
| 2019 | $14.26M | −$42.03M | −$23.59M |
| 2020 | $29.23M | −$26.58M | −$27.08M |
| 2022 | $34.42M | −$26.67M | −$19.62M |
| 2023 | $50.14M | −$35.38M | −$39.46M |
| 2024 | $64.25M | −$61.85M | −$58.27M |
| 2025 | $71.61M | −$48.59M | −$32.93M |
Revenue by region
Where Avita Medical Inc. generates its revenue.
- United States96%
- Japan3%
- Other1%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| United States | $33.26M | $46.36M | $62.16M | $68.79M | 96.1% |
| Japan | no data | $3.37M | $1.43M | $2.09M | 2.9% |
| Other | $1.16M | $0 | $663K | $735K | 1% |
| Total revenue | $34.42M | $50.14M | $64.25M | $71.61M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2023)
- Valuation signal Fairly valued since 13 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.